Lantern Pharma Inc. · NASDAQ:LTRN
CAVU MANAGEMENT, LP reported a 9.98% stake in Lantern Pharma Inc. (Schedule 13D/A)
Event Jun 12, 2025 · Filed Jun 13, 2025
CAVU MANAGEMENT, LP reported a 9.98% stake in Lantern Pharma Inc., 1,075,952 shares, with active intent on Jun 12, 2025. Filed Jun 13, 2025 (Schedule 13D/A).
- Stake
- 9.98%
- Shares
- 1,075,952
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOS FUND I, LP | 3.00% | 323,335 |
| BIOS FUND I QP, LP | 1.75% | 189,117 |
| BIOS FUND II, LP | 1.06% | 114,272 |
| BIOS FUND II QP, LP | 3.46% | 373,178 |
| BIOS FUND II NT, LP | 0.46% | 49,957 |
| BP DIRECTORS, LP | 0.24% | 26,093 |
| BIOS EQUITY PARTNERS, LP | 4.99% | 538,545 |
| BIOS EQUITY PARTNERS II, LP | 4.98% | 537,407 |
| CAVU MANAGEMENT, LP | 9.98% | 1,075,952 |
| BIOS CAPITAL MANAGEMENT, LP | 9.98% | 1,075,952 |
| CAVU ADVISORS, LLC | 9.98% | 1,075,952 |
| BIOS ADVISORS GP, LLC | 9.98% | 1,075,952 |
| LESLIE W. KREIS | 9.98% | 1,075,952 |
| AARON G.L. FLETCHER | 9.98% | 1,075,952 |
Source
Related
- Lantern Pharma Inc.
- Cavu Management, LP
- Lantern Pharma Inc. shareholders
- Schedule 13G/A · Empery Asset Management, LP · Oct 13, 2026
- Schedule 13G · Empery Asset Management, LP · Aug 4, 2026
- Schedule 13G/A · Thomas A. Satterfield, Jr. · Jul 23, 2026
- Schedule 13D/A · BIOS Advisors GP, LLC · May 15, 2026
- Form 4 · Schalop Lee Troy · May 14, 2026